复合人体因子VIIa的药物使用评估
Abrar Al-Subhi1, Mansoor Ahmed Khan1, Mohammed A Aseeri1
1Pharmaceutical Care Department, King Abdul-Aziz Medical City-Western Region, King Abdullah International Medical Research Center/King Saud bin Abdulaziz University for Health Sciences, Jeddah, Kingdom of Saudi Arabia.
Global journal on quality and safety in healthcare
|June 19, 2023
概括
这种药物使用评估发现,大多数复合人体因子VIIa (rFVIIa) 的使用是非标签的,尽管它的成本很高. 虽然大部分支出用于已批准的用途,但非标签处方代表着相当大的财务考虑.
科学领域:
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
- 临床药房 临床药房
背景情况:
- 药物使用评估 (MUE) 对于优化患者结果和管理医疗保健成本至关重要.
- 复合人体因子VIIa (rFVIIa) 是一种昂贵的药物,具有FDA批准的适用性.
- 非标签使用的rFVIIa是普遍存在的,引发了对疗效和财务影响的担忧.
研究的目的:
- 进行对复合人体因子VIIa (rFVIIa) 的药物使用评估.
- 为了确定在国王阿卜杜勒阿齐兹医疗城-西部地区 (KAMC-WR) 的rFVIIa非标签使用的程度.
- 评估与rFVIIa.a.的非标签使用相关的成本影响.
主要方法:
- 采用了观察性回顾性队列研究设计.
- 在一年内收集了患者人口统计数据,rFVIIa使用的适应症和相关成本.
- 分析的重点是确定非标签处方和计算直接支出.
主要成果:
- 在接受rFVIIa的27名患者中,有85% (23名患者) 患有非标签性适应症.
- 在研究期间,rFVIIa的总支出为SR18.61万 (4.96万美元).
- 大多数支出,95.8% (SR17.83百万) 是用于标签上的用途,尽管标签外处方的比例很高.
结论:
- 重组FVIIa是医院配方中的高成本药物.
- 在患有血友病A和抑制剂的患者中观察到rFVIIa的主要使用.
- 虽然非标签的使用很常见,但大多数财政资源都分配给标签上的说明.
相关概念视频
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
Rheumatic Heart Disease III: Medical Management
22
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
22


